A Phase 1b/2a Safety and Pharmacokinetic Study of CRLX101 (Formerly Named IT-101) [camptothecin] in the Treatment of Advanced Solid Tumours.

Trial Profile

A Phase 1b/2a Safety and Pharmacokinetic Study of CRLX101 (Formerly Named IT-101) [camptothecin] in the Treatment of Advanced Solid Tumours.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Camptothecin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Oct 2016 According to a Cerulean Pharma media release, data from the study will be presented at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting.
    • 06 Oct 2016 Results published in a Cerulean Pharma media release.
    • 31 Jul 2012 Actual end date (1 Apr 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top